Double-Blind Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5mg and 10mg twice daily) in Patients with Multiple Scclerosis, Acorda Theraupeutics Inc.